Latest Aperture Therapeutics News & Updates

See the latest news and media coverage for Aperture Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Aperture Therapeutics

Drug discovery platform for neurodegenerative diseases

aperturetx.com
Headquarters
San Carlos, United States
Founded year
2022
Company type
Private company
Number of employees
5–10

Last updated

Latest news about Aperture Therapeutics

In short: Aperture Therapeutics advanced its ALS and neurodegeneration pipeline through new drug programs, strategic licensing, and research awards.

Company announcements

Aperture Therapeutics

Aperture Therapeutics advances APRTX-003 program

APRTX-003 is a first-in-class antisense oligonucleotide targeting MMP9 to suppress neurodegeneration in ALS. It overcomes limitations of small molecules and antibodies.

Aperture Therapeutics

Aperture Therapeutics announces development candidate APRTX-001

APRTX-001 is a first-in-class CD33-targeting ASO suppressing microglial-driven neuroinflammation in ALS, FTD, AD, and PD. They thank NINDS and investors.

Unlock all announcements with a

Media coverage

Track future articles with a

Never miss news about Aperture Therapeutics

Track Aperture Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Aperture Therapeutics competitors & trending companies

Browse news for competitors to Aperture Therapeutics and other trending companies.